Stockreport

Galmed Pharmaceuticals Ltd. Unlocks CNS Potential with New Brain-Penetrating Aramchol Formulation [TheStreet.com]

Galmed Pharmaceuticals Ltd. - Ordinary Shares  (GLMD) 
Last galmed pharmaceuticals ltd. - ordinary shares earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: galmedpharma.investorroom.com
PDF advancement in its clinical development pipeline . The company is successfully developing a new, brain-penetrating formulation of its lead candidate, Aramchol. This brea [Read more]